AAIC 2021 | Investigating novel plasma-based P-tau biomarkers

A prerequisite for the testing of novel therapeutic agents is the identification of individuals most at risk for development or progression of Alzheimer’s disease pathology. Blood-based biomarkers have taken off in the dementia space in recent years, representing a more cost effective and accessible alternative to currently accepted imaging and cerebrospinal fluid (CSF) biomarkers. Nicholas Ashton, PhD, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden discusses the potential of P-tau231, a well-recognized CSF biomarker, as a plasma biomarker. While most evidence gathered to date suggests that P-tau231 performs similarly to P-tau181 and P-tau217, it may be more valuable in the preclinical setting. This interview took place during the Alzheimer’s Association International Conference (AAIC) 2021.